Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00136513
Status:
COMPLETED
Last Update Posted:
2008-10-16
First Post:
2005-08-25
Brief Title:
SB-743921 In Patients With Solid Tumors
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Administration of SB743921 on a Once Every 3 Week Schedule in Patients With Solid Tumors
Status:
COMPLETED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find a dose of SB-743921 in adult patients with solid tumors or lymphoma who have progressed on standard therapy or who have relapsed SB-743921 is dosed by 1-hour intravenous infusion every 3 weeks A patient may continue to receive treatment as long as they are benefiting from the treatment Blood samples will be taken at specific times to measure the amount of the drug in your body at specific times after the drug is given Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries Physical exams will be performed before each treatment with SB-743921 During the treatment phase the patients will undergo regular assessments for safety and clinical response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None